AI could slash contrast dye in breast MRIs
NCT ID NCT04340180
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 37 times
Summary
This study tested whether artificial intelligence (AI) can help doctors spot breast tumors on MRI scans that use a lower dose of the contrast agent gadolinium. Twenty women—half with benign findings and half with breast cancer—received both a standard-dose and a low-dose MRI. The AI's ability to identify and describe lesions was compared between the two scans. The goal is to reduce gadolinium exposure while keeping diagnostic accuracy high.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST BENIGN TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Kirklin Clinic
Birmingham, Alabama, 35249, United States
Conditions
Explore the condition pages connected to this study.